Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Foscarnet. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.37 |
| ▸ | MMP8 known ✓ | P22894 | 4/20 | 0.35 |
| ▸ | MMP1 known ✓ | P03956 | 3/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 4/20 | 0.35 |
| ▸ | MMP3 | P08254 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
| ▸ | CA9 | Q16790 | 3/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | MMP9 | P14780 | 2/20 | 0.30 |
| ▸ | PEPD | P12955 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Foscarnet SCHEMBL8862809 | 1.00 | MEN1 (0.37) | MEN1LMNAHPGDTSHRBLM | |
| Foscarnet SCHEMBL3678731 | 1.00 | MEN1 (0.37) | MEN1LMNAHPGDTSHRBLM | |
| Foscarnet SCHEMBL8169999 | 0.96 | BLM (0.39) | MEN1LMNAHPGDTSHRBLM | |
| Foscarnet SCHEMBL8863102 | 0.96 | BLM (0.39) | MEN1LMNAHPGDTSHRBLM | |
| Foscarnet SCHEMBL7637 | 0.96 | BLM (0.39) | MEN1LMNAHPGDTSHRBLM | |
| Foscarnet SCHEMBL7249084 | 0.96 | — | — | |
| Foscarnet SCHEMBL8862759 | 0.96 | BLM (0.39) | MEN1LMNAHPGDTSHRBLM | |
| Foscarnet SCHEMBL2689694 | 0.96 | — | — | |
| Foscarnet SCHEMBL5058619 | 0.96 | BLM (0.39) | MEN1LMNAHPGDTSHRBLM | |
| Foscarnet SCHEMBL23633 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1419803-B1 | Pharmaceutical composition for topical administration comprising an antiviral substance and a glucocorticoid | MEDIVIR AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| US-RE39264-E1 | Pharmaceutical combination | MEDIVIR AB (SE) | 2006-09-05 | — | — | US | disclosed |
| EP-1419803-A2 | Pharmaceutical composition for topical administration comprising an antiviral substance and a glucocorticoid | MEDIVIR AB (SE) | 2004-05-19 | — | — | EP | disclosed |
| EP-0809498-B1 | PHARMACEUITICAL COMPOSITION FOR TOPICAL APPLICATION CONTAINING ACYCLOVIR AND HYDROCORTISONE | MEDIVIR AB (SE) | 2004-03-31 | — | — | EP | disclosed |
| US-6337324-B1 | VIRICIDES AND ANTIINFLAMMATORY AGENTS | MEDIVIR, AB (SE) | 2002-01-08 | — | — | US | disclosed |
| US-6117857-A | FOR TREATMENT OF HERPESVIRUS INFECTIONS IN MAMMALS INCLUDING MAN, BY TOPICAL OR PARENTERAL ADMINISTRATION | ASTRA AKTIEBOLAG (SE) | 2000-09-12 | — | — | US | disclosed |
| US-6068860-A | FOR TOPICAL ADMINISTRATION COMPRISING FOSCARNET AND AN ANTIINFLAMMATORY GLUCOCORTICOID, WITH A CARRIER BASED ON GALACTOLIPIDS COMPRISING DIGALACTOSYLDIACYLGLYCEROLS, AND A POLAR SOLVENT; TREATING HERPES INFECTIONS | ASTRA AKTIEBOLAG (SE) | 2000-05-30 | — | — | US | disclosed |
| EP-0810865-A1 | NOVEL PHARMACEUTICAL COMPOSITION | Astra Aktiebolag (SE) | 1997-12-10 | — | — | EP | disclosed |
| EP-0809501-A1 | NOVEL PHARMACEUTICAL FORMULATION | Astra Aktiebolag (SE) | 1997-12-03 | — | — | EP | disclosed |
| EP-0809498-A1 | NOVEL PHARMACEUTICAL COMBINATION | Astra Aktiebolag (SE) | 1997-12-03 | — | — | EP | disclosed |
| WO-1996024359-A1 | NOVEL PHARMACEUTICAL FORMULATION | ASTRA AKTIEBOLAG (SE) | 1996-08-15 | — | — | WO | disclosed |
| WO-1996024354-A1 | NOVEL PHARMACEUTICAL COMPOSITION | ASTRA AKTIEBOLAG (SE) | 1996-08-15 | — | — | WO | disclosed |
| WO-1996024355-A1 | NOVEL PHARMACEUTICAL COMBINATION | ASTRA AKTIEBOLAG (SE) | 1996-08-15 | — | — | WO | disclosed |